Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and...

Area of Science:

• Immunology
• Vaccinology
• Cancer Research

Background:

• Vaccine platform comparisons traditionally focus on individual efficacy.
• Diversified prime-boost regimens can amplify antigen-specific T-cells.
• The potential for concurrent administration of distinct vaccine platforms remains underexplored.

Purpose of the Study:

• To investigate if two vaccine platforms targeting the same antigen induce shared and distinct T-cell populations.
• To examine the feasibility and impact of concomitantly administering two distinct vaccine types.

Main Methods:

• Comparison of T-cell populations induced by recombinant poxvirus and yeast vaccine platforms.
• Analysis of serum cytokine response, gene expression, T-cell receptor phenotype, and T-cell avidity.
• Assessment of antigen-specific T-cell tumor cell lysis.

Main Results:

• Both recombinant poxvirus and yeast vaccines elicit T-cell populations with shared and unique characteristics.
• The antigen and the vector independently influence the induction of distinct T-cell populations.
• Concurrent administration of the two vaccines resulted in a more diverse T-cell population.

Conclusions:

• Concurrent administration of distinct vaccine platforms targeting the same antigen enhances antitumor efficacy.
• This strategy leads to a broader and more effective antigen-specific immune response.
• Provides a rationale for clinical studies on combined vaccine platform administration for improved immunotherapy.